Novo reports 22.4% weight loss with CagriSema at 52 weeks in Milan
A separate real-world analysis of 194 patients switched from injectable GLP-1s to oral Wegovy showed 4.1% average weight loss over three months.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 12:30 ETSource: AD HOC NEWS
The wire
- 01At EASD in Milan, Novo Nordisk presented a 52-week obesity trial in which CagriSema cut body weight 22.4% versus placebo, with a companion analysis pointing to preserved bone balance.
- 02The OCTANE data, drawn from telemedicine platform Ro, give prescribers a first look at how patients moving from injectables to the Wegovy pill perform in routine practice.
- 03Novo said it would present 44 abstracts covering semaglutide, CagriSema and Zenagamtide; analyst price targets on the stock range from DKK 200 to DKK 457.
From the source
Read at ad-hoc-news.deNovo Nordisk's Oral Obesity Push Gains Traction as CagriSema Delivers 22.4% Weight Loss
Fresh clinical and real-world evidence landed in Milan on Wednesday, giving Novo Nordisk a double dose of data to bolster its metabolic portfolio. At the annual meeting of the European Association for the Study of Diabetes (EASD), the Danish drugmaker unveiled results for its lead combination candidate CagriSema alongside practical findings on switching patients to an oral formulation of Wegovy.
